{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:47:31Z","timestamp":1763142451152,"version":"3.44.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":140,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.100947","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T02:58:20Z","timestamp":1747969100000},"page":"100947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Observation of acute toxicity events in lung cancer patients treated concurrently with a tyrosine kinase inhibitor"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7024-3783","authenticated-orcid":false,"given":"Garrett K","family":"Harada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Ku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akul","family":"Munjal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Yeakel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuaib","family":"Juma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Maxim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Seyedin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misako","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2025.100947_bib0001","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.100947_bib0002","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.100947_bib0003","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet. Oncol"},{"key":"10.1016\/j.ctarc.2025.100947_bib0004","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctarc.2025.100947_bib0005","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctarc.2025.100947_bib0006","unstructured":"NCCN Clinical Practice Guidelines in oncology (NCCN Guidelines): non-small cell lung cancer (v 3.2023). In: NCCN [Internet]. [cited 30 Jun 2023]. Available: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"key":"10.1016\/j.ctarc.2025.100947_bib0007","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9572","article-title":"Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: data from a phase I\/II study","volume":"38","author":"Lee","year":"2020","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.ctarc.2025.100947_bib0008","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jtho.2021.10.024","article-title":"Efficacy of Aumolertinib (HS-10296) in patients with advanced EGFR T790M+ NSCLC: updated Post-National Medical Products Administration approval results from the APOLLO registrational trial","volume":"17","author":"Lu","year":"2022","journal-title":"J. Thorac. Oncol"},{"key":"10.1016\/j.ctarc.2025.100947_bib0009","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013Small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.ctarc.2025.100947_bib0010","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013Small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.ctarc.2025.100947_bib0011","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.radonc.2015.02.018","article-title":"Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest","volume":"115","author":"Kriegs","year":"2015","journal-title":"Radiother. Oncol"},{"key":"10.1016\/j.ctarc.2025.100947_bib0012","first-page":"77","article-title":"Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer","volume":"41","author":"Wang","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ctarc.2025.100947_bib0013","doi-asserted-by":"crossref","first-page":"39","DOI":"10.20892\/j.issn.2095-3941.2017.0118","article-title":"EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation","volume":"15","author":"Chen","year":"2018","journal-title":"Cancer Biol. Med"},{"key":"10.1016\/j.ctarc.2025.100947_bib0014","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s00066-022-01945-y","article-title":"Kinase inhibitors increase individual radiation sensitivity in normal cells of cancer patients","volume":"198","author":"Jost","year":"2022","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ctarc.2025.100947_bib0015","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.32876","article-title":"Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: analysis of over 8000 cases","volume":"126","author":"Mack","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2025.100947_bib0016","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with Osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.ctarc.2025.100947_bib0017","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant Osimertinib for resected EGFR-mutated stage IB-IIIA non\u2013Small-cell lung cancer: updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.ctarc.2025.100947_bib0018","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.radonc.2020.07.051","article-title":"An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib","volume":"152","author":"Jia","year":"2020","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol"},{"key":"10.1016\/j.ctarc.2025.100947_bib0019","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/j.ijrobp.2009.07.267","article-title":"Unexpected high lung toxicity from radiation pneumonitis in a phase I\/II trial of concurrent erlotinib with limited field radiation for intermediate prognosis patients with stage III or inoperable stage IIB non\u2013small-cell lung cancer(NSCLC)","volume":"75","author":"Wan","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys"},{"key":"10.1016\/j.ctarc.2025.100947_bib0020","first-page":"69","article-title":"A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer","volume":"5","author":"Center","year":"2010","journal-title":"J. Thorac Oncol Off Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.ctarc.2025.100947_bib0021","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/1759-7714.13816","article-title":"Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer","volume":"12","author":"Xu","year":"2021","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.ctarc.2025.100947_bib0022","article-title":"Thoracic stereotactic body radiation therapy plus first-line tyrosine kinase inhibitors for patients with epidermal growth factor receptor-mutant polymetastatic non-small-cell lung cancer","volume":"100","author":"Wang","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.ctarc.2025.100947_bib0023","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1634\/theoncologist.2019-0285","article-title":"Concurrent EGFR-TKI and thoracic radiotherapy as first-line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations","volume":"24","author":"Zheng","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2025.100947_bib0024","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.ijrobp.2010.12.035","article-title":"Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer","volume":"81","author":"Wang","year":"2011","journal-title":"Int. J. Radiat Oncol Biol. Phys."},{"key":"10.1016\/j.ctarc.2025.100947_bib0025","first-page":"djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC","author":"Wang","year":"2022","journal-title":"J. Natl. Cancer Inst"},{"key":"10.1016\/j.ctarc.2025.100947_bib0026","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation dose volume effects in the lung","volume":"76","author":"Marks","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys"},{"key":"10.1016\/j.ctarc.2025.100947_bib0027","article-title":"Randomized Phase II trial of Osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR)","author":"Elamin","year":"2021","journal-title":"Clinicaltrials.Gov."},{"key":"10.1016\/j.ctarc.2025.100947_bib0028","article-title":"A phase II randomized controlled trial of TKI alone versus TKI and local consolidative radiation therapy in oncogene driver mutated oligo metastatic non small cell lung cancer patients","author":"Tibdewal","year":"2022","journal-title":"Clinicaltrials.Gov."},{"journal-title":"Clinicaltrials.Gov.","year":"2022","author":"Ramalingam","key":"10.1016\/j.ctarc.2025.100947_bib0029"},{"key":"10.1016\/j.ctarc.2025.100947_bib0030","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.2217\/fon-2021-0549","article-title":"Neoadjuvant osimertinib with\/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: neoADAURA","volume":"17","author":"Tsuboi","year":"2021","journal-title":"Future. Oncol. Lond. Engl"},{"key":"10.1016\/j.ctarc.2025.100947_bib0031","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13014-021-01765-x","article-title":"Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy","volume":"16","author":"Jia","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctarc.2025.100947_bib0032","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1001\/jamaoncol.2021.7664","article-title":"Palliative radiation for advanced Central lung tumors with intentional avoidance of the esophagus (PROACTIVE): a phase 3 randomized clinical trial","volume":"8","author":"Louie","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctarc.2025.100947_bib0033","first-page":"15","article-title":"Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective","volume":"33","author":"Eckstein","year":"2014","journal-title":"J. Exp. Clin. Cancer Res. CR"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T21:14:11Z","timestamp":1756934051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225000838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":33,"alternative-id":["S2468294225000838"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100947","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Observation of acute toxicity events in lung cancer patients treated concurrently with a tyrosine kinase inhibitor","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100947","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100947"}}